Business Description
Cadence Pharmaceuticals, Inc.
ISIN : US12738T1007
Compare
Compare
Traded in other countries / regions
QEW.Germany Description
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -21.47 |
GF Value Rank
| Name | Current | Vs Industry | Vs History |
|---|
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cadence Pharmaceuticals, Inc. Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 84.369 | ||
| EPS (TTM) (€) | -0.216 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 4.74 - 14.24 | ||
| Shares Outstanding (Mil) | 86.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cadence Pharmaceuticals, Inc. Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cadence Pharmaceuticals, Inc. Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cadence Pharmaceuticals, Inc. Frequently Asked Questions
What is Cadence Pharmaceuticals, Inc.(FRA:QEW)'s stock price today?
The current price of FRA:QEW is €9.95. The 52 week high of FRA:QEW is €14.24 and 52 week low is €4.74.
When is next earnings date of Cadence Pharmaceuticals, Inc.(FRA:QEW)?
The next earnings date of Cadence Pharmaceuticals, Inc.(FRA:QEW) is .
Does Cadence Pharmaceuticals, Inc.(FRA:QEW) pay dividends? If so, how much?
Cadence Pharmaceuticals, Inc.(FRA:QEW) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers